Hear from the experts in the field of early-stage breast cancer on the performance and utility of the Prosigna® breast cancer prognostic gene signature. From current to emerging treatment options, the speaker panel will discuss different biomarker strategies that support shared decision-making for the management of hormone-receptor positive (HR+) patients. Bonnie Anderson, CEO of Veracyte (San Francisco, USA), will introduce this webinar and explain her company’s key role in the application of advanced genomics towards the development of globally available in-vitro diagnostic assays that are uniquely designed to answer today’s unmet clinical needs.
Prosigna® Breast Cancer Prognostic Gene Signature Assay (Prosigna assay) for use on the nCounter Dx analysis system is 510(k) cleared for in vitro diagnostic use in prognosis and surgical resection. See Package Insert in www.prosigna.com for details. Content in these presentations expands beyond information related to FDA and CE-marked product claims. Please refer to region specific Package Inserts for the respective product claims. Intrinsic molecular subtypes are not reported by the Prosigna assay cleared by the FDA in the United States. However, intrinsic molecular subtypes identified by the gene signature are utilized by the algorithm to calculate the Prosigna Score (ROR) and risk category.